Class / Patent application number | Description | Number of patent applications / Date published |
514427000 | Two double bonds between ring members of the five-membered hetero ring (e.g., pyrrole, etc.) | 24 |
20080249158 | PYRROLE DERIVATIVES AS THERAPEUTIC COMPOUNDS - Novel pyrrole derivatives are disclosed as Aβ | 10-09-2008 |
20080262074 | Salt Forms of [R-(R*,R*)]-2-(4-Fluorophenyl)-Beta,Delta-Dihydroxy-5-(1-Methylethyl)-3-(Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic Acid - Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid or solvates or hydrates thereof, as well as crystalline salts characterized by their X-ray powder diffraction pattern are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease. | 10-23-2008 |
20090018183 | N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands - The present invention provides novel compounds of the general Formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: | 01-15-2009 |
20090088465 | Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same - Solid pharmaceutical compositions containing atorvastatin are disclosed. The compositions include a solid dispersion of amorphous atorvastatin and one or more optional pharmaceutically acceptable excipients. The solid dispersion is prepared by mixing crystalline atorvastatin with a melt-processable polymer and an optional stabilizer at a temperature sufficiently high to soften or melt the polymer and to melt or dissolve the crystalline atorvastatin in the polymer, thereby forming a dispersion of amorphous atorvastatin. | 04-02-2009 |
20090253768 | THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS - Pyrrole derivatives are disclosed as agents for the treatment and prevention of neuropathies and neurodegenerative diseases characterized by the presence of axonal blockages, impaired axonal transport or impaired trafficking of vesicles in neurons. | 10-08-2009 |
20090264500 | 3-SUBSTITUTED-1,5-DIARLY-2-ALKYL-PYRROLES HIGHLY SELECTIVE AND ORALLY EFFECTIVE COX-2 INHIBITORS - This invention relates to 3-substituted-1,5-diaryl-2-alkyl-pyrroles of Formula I, pharmaceutical compositions containing them, and to their use for the pharmacological treatment of pain and COX-2 over-activation associated disorders. Compounds of this invention are new pyrrole derivatives bearing in position-3 of the pyrrole ring, several variously functionalized, not aliphatic, side chains which confer to the compounds a relevant COX-2 potency and selectivity along with a remarkable oral efficacy. Phenyl rings in position-1 and -5 are variously substituted, but compounds of particular interest are those substituted in position-5 with 4-methylsulphonyl-phenyl or with 4-aminosulphonyl-phenyl groups. | 10-22-2009 |
20090326038 | Method for treating a immunology-related disease - A method for treating an immunology-related disease. The method involves administering to a mammal in need thereof a pharmaceutically effective amount of an amino acid compound, a pharmacologically acceptable salt thereof or a pharmacologically acceptable ester thereof. The compound has the following formula: | 12-31-2009 |
20100056605 | OXIDATIVE DEGRADATION PRODUCTS OF ATORVASTATIN CALCIUM - The present invention relates to oxidative degradation products of atorvastatin calcium and the process of the preparation thereof. The present invention also relates to atorvastatin calcium substantially free of oxidative degradation products and the pharmaceutical compositions containing such atorvastatin calcium. | 03-04-2010 |
20100216862 | Pyrrole Derivatives As Therapeutic Compounds - Novel pyrrole derivatives are disclosed as Aβ | 08-26-2010 |
20110082183 | PHENYL PYRROLE AMINOGUANIDINE DERIVATIVES - The present invention relates to phenyl pyrrole aminoguanidine derivatives of the general formula (I): (I) including tautomeric forms thereof, wherein n is 1, 2 or 3; or a pharmaceutically acceptable salt thereof. The present invention further relates to the use of such phenyl pyrrole aminoguanidine derivatives for the treatment of diseases associated with the melanocortin receptors or related systems, e.g. the melanocyte stimulating hormones. | 04-07-2011 |
20110160275 | SYNERGISTIC ANTIFOULING COMPOSITIONS COMPRISING 4-BROMO-2-(4-CHLOROPHENYL)-5-(TRIFLUOROMETHYL)-1H-PYRROLE-3-CARBONITRILE - The present invention relates to antifouling compositions and particularly to compositions which are able to provide an improved protecting effect against fouling organisms. More particularly, the present invention relates to synergistic antifouling compositions comprising an amount of at least 3.5 wt %, based on the total weight of the dry mass of the composition, of 4-bromo-2-(4-chlorophenyl)-5-(trifluoromethyl)-1H-pyrrole-3-carbonitrile, or a salt thereof, together with another biocide selected from bethoxazin, tolylfluanide, dichlofluanide, or DCOIT; for protecting materials against fouling organisms. This invention thus relates to the field of protection of materials, such as underwater objects, protection of wood, wood products, biodegradable materials and coatings. | 06-30-2011 |
20110184040 | Method for Controlling Arthropods Comprising the Spot-Wise Application of a Gel - The present invention relates to a method for controlling arthropods comprising the application of an aqueous gel which contains an insecticide, an attractant and a thickener, wherein the aqueous gel is applied in the form of spots on fruit trees. The invention further relates to an aqueous gel comprising an insecticide, an attractant, a thickener, a humectant and a feeding stimulant. The invention also relates to a concentrated gel for preparing the aqueous gel. | 07-28-2011 |
20120016002 | Patient Selection and Therapeutic Methods Using Markers of Prostaglandin Metabolism - Disclosed herein are methods related generally to a patient selection process for identifying individuals for treatment of cancer, inflammation, pain, and/or related conditions. | 01-19-2012 |
20120196915 | Antitumor 1,2-Diphenylpyrrole Compounds and their Preparation Process - The present invention relates to a new series of 1,2-diphenylpyrroles of formula (I) or their pharmaceutically acceptable salts, or their pharmaceutically acceptable solvates, having antitumor activity, wherein R | 08-02-2012 |
20130165494 | 1,5-Diaryl-2-alkylpyrrole-3-Substituted Nitro Esters, Selective COX-2 Inhibitors and Nitric Oxide Donors - 1,5-diaryl-2-alkylpyrrole-3-substituted nitro esters, of Formula (I) | 06-27-2013 |
20130303585 | SMALL MOLECULE RNASE INHIBITORS AND METHODS OF USE - Small molecule inhibitors of bacterial ribonuclease (e.g., RnpA) and methods for their synthesis and use are described herein. The methods of using the compounds include treating and preventing microbial infections and inhibiting bacterial ribonuclease. Also described herein are methods of identifying compounds for treating or preventing a microbial infection. | 11-14-2013 |
20130338209 | TREATMENT FOR LIPODYSTROPHY - The present invention provides a therapeutic compound of formula (I) and their pharmaceutically acceptable salts for the prevention and treatment of lipodystrophy caused because of HIV infection or combination therapy of HIV-1 protease inhibitors (Pis) and/or reverse transcriptase inhibitors (nRTIs) by neutralizing lipohypertrophy, lipoatrophy and metabolic abnormalities in HIV patient. | 12-19-2013 |
20140309274 | Lipidic Furan, Pyrrole, and Thiophene Compounds for Treatment of Cancer, Neurological Disorders, and Fibrotic Disorders - Compounds, methods, and compositions are provided for the treatment of cancer, neurological disorders, and fibrotic disorders. Specifically, the invention includes administering an effective amount of a compound of Formula I, II, or III, or a pharmaceutically acceptable composition, salt, isotopic analog, prodrug, or combination thereof, to a subject suffering from a cancer, neurological disorder, or fibrotic disorder. | 10-16-2014 |
20150327543 | SOLID AGROFORMULATIONS FOR PREPARING NEAR MICRO-EMULSION AQUEOUS PESTICIDES - Disclosed are extruded pesticide granules that when mixed with water form a near micro-emulsion that is highly stable. The extruded pesticide granules include at least one pesticide active ingredient, a non-ionic surfactant, and a carrier, which is desirably urea powder or urea pearl. Processes for making the extruded pesticide granules are also disclosed. | 11-19-2015 |
20160107989 | A PROCESS FOR PREPARATION OF PYRROLES HAVING HYPOLIPIDEMIC HYPOCHOLESTEREMIC ACTIVITIES - The present invention provides pyrroles having hypolipidemic hypocholesteremic activities. The invention provides saroglitazar and its pharmaceutically acceptable salts, hydrates, solvates, polymorphs or intermediates thereof. The invention also provides a process for the preparation of saroglitazar. The invention further provides intermediates as well process for preparation thereof. | 04-21-2016 |
20160115124 | SMALL MOLECULE RNASE INHIBITORS AND METHODS OF USE - Small molecule inhibitors of bacterial ribonuclease (e.g., RnpA) and methods for their synthesis and use are described herein. The methods of using the compounds include treating and preventing microbial infections and inhibiting bacterial ribonuclease. Also described herein are methods of identifying compounds for treating or preventing a microbial infection. | 04-28-2016 |
20160136131 | FORMULA COMPRISING A HYPOLIPIDEMIC AGENT - The present invention relates to the stable pharmaceutical composition of a suitable hypolipidemic agent. Preferably, the present invention discloses novel formulations of the compound of formula (I), or pharmaceutically acceptable salts of compounds of formula (I). More particularly the present invention relates to the stable pharmaceutical composition of compounds of formula (I) comprising compounds of formula (I) or its pharmaceutically acceptable salts, wherein the pH of the formulation is maintained above 7. | 05-19-2016 |
20160166539 | A NOVEL COMPOSITION FOR NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) | 06-16-2016 |
20160194280 | IMPROVED PROCESS FOR THE PREPARATION OF PYRROLE DERIVATIVES | 07-07-2016 |